Details for Patent: 6,395,767

Summary for Patent: 6,395,767

Title:	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Abstract:	Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula ##STR1## where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
Inventor(s):	Robl; Jeffrey A. (Newtown, PA), Sulsky; Richard B. (West Trenton, NJ), Augeri; David J. (Princeton, NJ), Magnin; David R. (Hamilton, NJ), Hamann; Lawrence G. (Cherry Hill, NJ), Betebenner; David A. (Lawrenceville, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	09/788,173
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,395,767
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,395,767

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,395,767

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	027634
Austria	396176
Australia	2001245466
Australia	4546601